New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
18:28 EDTBIIBBiogen announces FDA approval for Alprolix
Biogen Idec announced that the U.S. FDA has approved Alprolix, the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. Alprolix is indicated for the control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B. The therapy is shown to reduce bleeding episodes with prophylactic infusions starting at least a week apart. Alprolix was recently approved by Health Canada for the treatment of hemophilia B and is currently under review by regulatory authorities in several other countries, including Australia and Japan. Biogen Idec plans to make Alprolix commercially available to people with hemophilia B in the United States in early May.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 7, 2014
07:24 EDTBIIBAlliance for Regenerative Medicine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use